Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024. The company was founded in 2019 and is headquartered in Berkeley Heights, New Jersey. Show more
400 Connell Drive, Berkeley Heights, NJ, 07922, United States
Market Cap
132.8M
52 Wk Range
$2.14 - $11.88
Previous Close
$5.94
Open
$5.75
Volume
23,572
Day Range
$5.53 - $6.10
Enterprise Value
19.55M
Cash
118M
Avg Qtr Burn
-7.057M
Insider Ownership
10.27%
Institutional Own.
78.86%
Qtr Updated
12/31/25
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
TH103 Details Neovascular Age-Related Macular Degeneration (nAMD) | Phase 1/2 Data readout |